Lexicon Pharmaceuticals (LXRX) News Today $0.71 -0.01 (-1.23%) (As of 12/20/2024 05:45 PM ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period Lexicon Pharmaceuticals, Inc.: Lexicon Announces Receipt of Complete Response Letter for Zynquista (sotagliflozin)December 21 at 6:43 AM | finanznachrichten.deLexicon Receives Complete Response Letter from FDA for Diabetes, Kidney Disease TreatmentDecember 20 at 8:41 PM | marketwatch.comLexicon receives CRL for ZynquistaDecember 20 at 8:41 PM | markets.businessinsider.comFDA rejects Lexicon's Zynquista for diabetes, kidney diseaseDecember 20 at 8:41 PM | msn.comLexicon Pharmaceuticals Receives Complete Response Letter from FDA for Zynquista™ NDADecember 20 at 5:13 PM | quiverquant.comUS FDA declines to approve Lexicon Pharma's add-on diabetes drugDecember 20 at 4:46 PM | reuters.comLexicon Announces Receipt of Complete Response Letter for Zynquista™ (sotagliflozin)December 20 at 4:30 PM | globenewswire.comPromising Investment Opportunity in Lexicon Pharmaceuticals’ LX9211 for Diabetic Peripheral Neuropathic PainDecember 13, 2024 | markets.businessinsider.comPoint72 Asset Management L.P. Reduces Stock Holdings in Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX)Point72 Asset Management L.P. lowered its holdings in shares of Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX - Free Report) by 70.2% in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 1,230,050 shares of the biopharmaceutical compDecember 10, 2024 | marketbeat.comLexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Stock Holdings Boosted by Fmr LLCFmr LLC lifted its position in shares of Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX - Free Report) by 28.9% in the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 49,867,042 shares of the biopharmaceutical company's stock after acquiring an additional 11,179,919 shDecember 6, 2024 | marketbeat.comBraidwell LP Has $1.26 Million Stock Holdings in Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX)Braidwell LP decreased its stake in Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX - Free Report) by 90.3% in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 801,584 shares of the biopharmaceutical company's stock after selling 7,493,November 29, 2024 | marketbeat.comLexicon announces completion of enrollment in Phase 2B PROGRESS studyNovember 26, 2024 | markets.businessinsider.comLexicon Pharmaceuticals: Strategic Focus on Promising Pipeline Amid Clinical Progress and RestructuringNovember 26, 2024 | markets.businessinsider.comLexicon Pharmaceuticals Completes Patient Enrollment for PROGRESS Study of LX9211, Exceeding Targets by 20%November 26, 2024 | quiverquant.comLexicon Announces Completion of Enrollment in Phase 2B PROGRESS Study of LX9211 in Diabetic Peripheral Neuropathic Pain (DPNP)November 26, 2024 | globenewswire.comLexicon Pharmaceuticals to Participate in December Investor ConferencesNovember 25, 2024 | globenewswire.comLexicon Pharmaceuticals to cut 60% of workforceNovember 24, 2024 | investing.comLexicon Pharmaceuticals (LXRX) Receives a Hold from NeedhamNovember 23, 2024 | markets.businessinsider.comLexicon to eliminate commercial organization, focus on clinical developmentNovember 22, 2024 | markets.businessinsider.comLexicon Pharmaceuticals to lay off 60% of workforce after FDA setbackNovember 22, 2024 | msn.comNeedham & Company LLC Reaffirms "Hold" Rating for Lexicon Pharmaceuticals (NASDAQ:LXRX)Needham & Company LLC reiterated a "hold" rating on shares of Lexicon Pharmaceuticals in a research report on Friday.November 22, 2024 | marketbeat.comLexicon Pharmaceuticals Announces Strategic Restructuring to Focus on R&D and Cut Operating Costs by $100 MillionNovember 22, 2024 | quiverquant.comLexicon Pharmaceuticals to cut workforce by 60% to focus on drug developmentNovember 22, 2024 | reuters.comLexicon to Reposition as Clinical Development-Focused Company Following Regulatory Update From FDANovember 22, 2024 | globenewswire.comLexicon Pharmaceuticals Appoints Ivan Cheung to BoardNovember 20, 2024 | markets.businessinsider.comIvan H. Cheung Elected to Board of Directors of Lexicon Pharmaceuticals, Inc.November 20, 2024 | quiverquant.comLexicon Appoints Ivan H. Cheung to Board of DirectorsNovember 20, 2024 | globenewswire.comLexicon Pharmaceuticals (LXRX) Stock Plummets Amidst Market ActivityNovember 20, 2024 | gurufocus.comLexicon Pharmaceuticals (NASDAQ:LXRX investor three-year losses grow to 80% as the stock sheds US$107m this past weekNovember 18, 2024 | finance.yahoo.comLeerink Partnrs Has Bullish Outlook for LXRX Q4 EarningsLexicon Pharmaceuticals, Inc. (NASDAQ:LXRX - Free Report) - Stock analysts at Leerink Partnrs raised their Q4 2024 EPS estimates for shares of Lexicon Pharmaceuticals in a research report issued to clients and investors on Thursday, November 14th. Leerink Partnrs analyst R. Ruiz now expects thatNovember 18, 2024 | marketbeat.comWhat is HC Wainwright's Forecast for LXRX FY2024 Earnings?Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX - Free Report) - Stock analysts at HC Wainwright decreased their FY2024 earnings estimates for shares of Lexicon Pharmaceuticals in a research report issued to clients and investors on Wednesday, November 13th. HC Wainwright analyst J. Pantginis now foreNovember 15, 2024 | marketbeat.comLexicon announces data from four stories of sotagliflozin to be deliveredNovember 14, 2024 | markets.businessinsider.comLexicon Pharmaceuticals Reports Q3 2024 Financial ResultsNovember 14, 2024 | markets.businessinsider.comDemystifying Lexicon Pharmaceuticals: Insights From 10 Analyst ReviewsNovember 13, 2024 | benzinga.comLexicon Pharmaceuticals: Strategic Advancements and Financial Stability Justify Buy RatingNovember 13, 2024 | markets.businessinsider.comLexicon Pharmaceuticals (LXRX) Gets a Buy from Piper SandlerNovember 13, 2024 | markets.businessinsider.comLexicon Pharmaceuticals' (LXRX) "Hold" Rating Reaffirmed at Needham & Company LLCNeedham & Company LLC reiterated a "hold" rating on shares of Lexicon Pharmaceuticals in a report on Wednesday.November 13, 2024 | marketbeat.comLexicon Pharmaceuticals (NASDAQ:LXRX) Receives "Buy" Rating from HC WainwrightHC Wainwright reaffirmed a "buy" rating and issued a $6.00 price objective on shares of Lexicon Pharmaceuticals in a research note on Wednesday.November 13, 2024 | marketbeat.comLexicon Pharmaceuticals Inc (LXRX) Q3 2024 Earnings Call Highlights: Strategic Advances Amidst ...November 13, 2024 | finance.yahoo.comLexicon Pharmaceuticals options imply 14.8% move in share price post-earningsNovember 13, 2024 | markets.businessinsider.comLexicon Pharmaceuticals, Inc. (LXRX) Q3 2024 Earnings Call TranscriptNovember 12, 2024 | seekingalpha.comLexicon Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business UpdateNovember 12, 2024 | globenewswire.comPreview: Lexicon Pharmaceuticals's EarningsNovember 11, 2024 | benzinga.comLexicon Pharmaceuticals Q3 2024 Earnings PreviewNovember 11, 2024 | msn.comLexicon Pharmaceuticals Inc (LXRX) Q3 2024 Earnings Report Preview: What To Look ForNovember 11, 2024 | finance.yahoo.comLexicon Pharmaceuticals (LXRX) Scheduled to Post Earnings on TuesdayLexicon Pharmaceuticals (NASDAQ:LXRX) will be releasing earnings after the market closes on Tuesday, November 12, Zacks reports.November 6, 2024 | marketbeat.comLexicon Pharmaceuticals to Participate in the Jefferies London Global Healthcare ConferenceNovember 6, 2024 | globenewswire.comPublished Data in Journal of American Society of Nephrology Highlights Findings on Efficacy and Safety of Sotagliflozin for People With Type 1 Diabetes and Chronic Kidney DiseaseNovember 5, 2024 | globenewswire.comLexicon Pharmaceuticals' (LXRX) Buy Rating Reiterated at HC WainwrightHC Wainwright reissued a "buy" rating and set a $6.00 target price on shares of Lexicon Pharmaceuticals in a research note on Tuesday.November 5, 2024 | marketbeat.comLexicon to present data from two studies related to LX9851November 4, 2024 | markets.businessinsider.com Get Lexicon Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for LXRX and its competitors with MarketBeat's FREE daily newsletter. Email Address We recommended Palantir in 2021, now we’re recommending this... (Ad)My research indicates there is only one investment that can meet AI's unprecedented demand for energy. Click to get the name and ticker symbol LXRX Media Mentions By Week LXRX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. LXRX News Sentiment▼0.000.60▲Average Medical News Sentiment LXRX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. LXRX Articles This Week▼74▲LXRX Articles Average Week Get Lexicon Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for LXRX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies IRWD News SGMO News EBS News CDXS News RIGL News XOMA News VNDA News VSTM News ACHV News RGLS News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:LXRX) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTop Picks for Trump’s Pro-Crypto AmericaCoins Set to Soar with a Pro-Crypto White House President-Elect Donald Trump is reported to be holding over...Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lexicon Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lexicon Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
